Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2002

View Archived Issues

Cell therapy as a treatment for myocardial infarction and heart failure

Endo updates investors at healthcare conference

Squalamine enters clinical trials for fibrodysplasia ossificans progressiva

Generex's buccal morphine demonstrates proof of concept in phase I study

AtheroGenics aggressively developing lead compound

ProSorb formulation of pain medication enters pivotal trials

Activity and adequate safety demonstrated in phase II trial of Onconase in malignant mesothelioma

Orally and topically administered C5a antagonist effective in dermal immunoinflammatory reaction

Potent and selective ETA receptor antagonist potently lowers blood pressure in rats

Efficacy of novel mucosal vaccine delivery system described by RxKinetix in recent article

Corixa and Beaufour Ipsen collaborate on AnergiX.MG technology for myasthenia gravis

Oxford GlycoSciences, Medarex and Genmab in new initiative against cancer

Enbrel approved for treatment of psoriatic arthritis

Phase 2 Discovery to develop LY-156735 for sleep disorders

Risedronate receives approval in Japan

Alizyme's mucositis drug ATL-104 proves safe and well tolerated in phase Ia trial

Board recommends continuing phase III trial of Actimmune for IPF

Alliance looks to resume phase III program for Oxygent

Palonosetron completes phase III trials for CINV

New NK1 receptor antagonists described recently by Roche

Preparation and use of new thiourea NPY Y1 antagonists for eating disorders

Anticoagulants derived from phenylglycine at Roche

European scientists design triterpenoids which inhibit CDKs

MMP inhibitors and potential uses thereof reported by Aventis

Vertex researchers synthesize series of caspase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...